Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.
نویسندگان
چکیده
Bevacizumab (Avastin, Genentech) is a recombinant humanised, full length, antiVEGF monoclonal antibody that binds all isoforms of VEGF-A. It has been shown to prolong survival of patients with advanced colon cancer when combined with 5-fluorouracil. In this report, we describe the effect of bevacizumab in two patients with choroidal neovascularisation (CNV) secondary to pathological myopia, which was refractory to other treatment.
منابع مشابه
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review
OBJECTIVES The aim of this study is to systematically review the evidence for anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularisation secondary to conditions other than age-related macular degeneration. DATA SOURCES MEDLINE, MEDLINE in-process, EMBASE and CENTRAL databases and conference abstracts were searched (from inception to Jan 2014). STUDY ELIGIBILITY C...
متن کاملIntravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
BACKGROUND To determine the efficacy and safety of intravitreal Avastin (bevacizumab) in the treatment of choroidal neovascularisation (CNV) secondary to pathological myopia (PM). METHODS This paper reports on a consecutive prospective study of patients with CNV secondary to PM who were treated with intravitreal bevacizumab (1.25 mg/0.05 ml). Patients underwent complete ophthalmic evaluation,...
متن کاملIntravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population.
Dear Editor, Myopic choroidal neovascularisation (mCNV) is one of the most common causes of permanent central visual loss in patients with high myopia,1 and its natural history results in the development of chorioretinal atrophy around the regressed mCNV, causing further progressive central visual loss.2 Therefore there is a need to fi nd treatment options which will not only regress the mCNV b...
متن کاملLong-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia.
AIM To evaluate the long-term results and prognostic factors of intravitreal bevacizumab (IVB) for myopic choroidal neovascularisation (mCNV). METHODS Thirty-two eyes of 30 patients with mCNV were included in a prospective case series. Treatment consisted of three monthly 1.25 mg IVB injections. Best corrected visual acuity (BCVA) and CNV area were compared before and after treatment. Prognos...
متن کاملInadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
INTRODUCTION This study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant. CLINICAL PICTURE A 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes. TREATMENT Both eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially. OUTCOME Vision improved signific...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The British journal of ophthalmology
دوره 89 10 شماره
صفحات -
تاریخ انتشار 2005